XML 22 R5.htm IDEA: XBRL DOCUMENT v3.25.4
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Income Statement [Abstract]    
Revenues
Operating Expenses:    
Research and development 9,156,474 11,906,601
General and administrative 18,532,843 18,249,402
Stock-based compensation – general and administrative 10,836,291 11,839,678
Total Operating Expenses 38,525,608 41,995,681
Operating Loss (38,525,608) (41,995,681)
Other Income (Expense):    
Interest income 110,081 758,000
Interest expense (267,782)
Gain on sale of New Jersey net operating losses 2,387,842
Total Other Income (Expense), Net (157,701) 3,145,842
Loss before Income Taxes (38,683,309) (38,849,839)
Income tax expense 1,056,960 576,000
Net Loss (39,740,269) (39,425,839)
Net loss attributable to non-controlling interest 2,306,358 287,000
Deemed dividend on warrant extension (1,047,312)
Net Loss Applicable to Common Stockholders $ (37,433,911) $ (40,186,151)
Net Loss Per Share Applicable to Common Stockholders - Basic (in Dollars per share) $ (3.38) $ (5.97)
Net Loss Per Share Applicable to Common Stockholders - Diluted (in Dollars per share) $ (3.38) $ (5.97)
Weighted Average Common Shares Outstanding    
Basic (in Shares) 11,065,225 6,726,999
Diluted (in Shares) 11,065,225 6,726,999